Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
02 Dezember 2008 - 1:30PM
PR Newswire (US)
IRVINE, Calif., Dec. 2 /PRNewswire-FirstCall/ -- Cardiogenesis
Corporation (Pink Sheets: CGCP), a leading developer of surgical
products used in the treatment of patients suffering from severe
angina, today announced the addition of veteran medical device
executive and an experienced public company director, Raymond W.
Cohen as a member of the Company's Board of Directors, increasing
the number of board members to six. Mr. Cohen, 49, has over 25
years of executive experience in the medical technology field and
is currently the Chief Executive Officer and a member of the Board
of Directors of Symphony Medical Inc., a venture-capital backed
developer of novel biotherapeutic therapies to treat heart failure
and other cardiac abnormalities. For the decade prior to 2006,
Cohen served as Chairman and CEO of publicly traded Cardiac
Science, Inc. having served in that role during the period of rapid
revenue growth and through the company's merger with Quinton
Cardiology in late 2005. Today Cardiac Science is a leading
manufacturer of automated public-access defibrillators and
diagnostic cardiology systems, generating over $200 million in
annual revenue. Cohen continues to serve on the board of Cardiac
Science and also serves on the boards of BioLife Solutions, Inc., a
publicly traded company, and BioGenex, Inc., and Syncroness, Inc.
Paul J. McCormick, the Company's Chairman of the Board commented,
"Mr. Cohen has a solid track record of success in developing and
commercializing innovative medical technology, particularly in the
cardiovascular market. He brings the vision, insight and skills
necessary to make a significant contribution to the Cardiogenesis
Board of Directors and our shareholders. We are very pleased to
have Mr. Cohen join our board and look forward to working with
him." About Cardiogenesis Corporation Cardiogenesis specializes in
providing surgical devices to treat cardiovascular disease and
severe angina. The Company's market leading holmium:YAG laser
system and single use fiber-optic delivery systems are used to
perform a procedure known as Transmyocardial Revascularization
(TMR). To date, thousands of patients have been treated with the
Cardiogenesis TMR technology. For more information on
Cardiogenesis, please visit the Company's website at
http://www.cardiogenesis.com/. Cardiogenesis also maintains a
website where patients suffering from angina can learn more about
the TMR procedure at http://www.heartofnewlife.com/. Safe Harbor
Statement With the exception of historical information, the
statements set forth above include forward-looking statements. Any
forward-looking statements in this news release related to the
possible effectiveness of the Company's technologies and the effect
of such technologies on the Company's sales, profitability, the
adoption of its technology and products and FDA clearances are
based on current expectations and beliefs and are subject to
numerous risks and uncertainties, many of which are outside the
Company's control, that could cause actual results to differ
materially. Factors that could affect the accuracy of these
forward-looking statements include, but are not limited to: any
inability by the Company to sustain profitable operations or obtain
additional financing on favorable terms if and when needed; any
failure to obtain required regulatory approvals; failure of the
medical community to expand its acceptance of TMR procedures;
possible adverse governmental rulings or regulations, including any
FDA regulations or rulings; the Company's ability to comply with
international and domestic regulatory requirements; possible
adverse Medicare or other third-party reimbursement policies or
adverse changes in those policies; any inability by the Company to
ship product on a timely basis; the Company's ability to manage its
growth; the effects of recent disruptions in global credit and
equity markets and other adverse economic developments that could
adversely affect the market for our products or our ability to
raise needed financing; actions by our competitors; and the
Company's ability to protect its intellectual property. Other
factors that could cause Cardiogenesis' actual results to differ
materially are discussed in the "Risk Factors" section of the
Company's Annual Report on Form 10-KSB for the year ended December
31, 2007 and the Company's other recent SEC filings. The Company
disclaims any obligation to update any forward-looking statements
as a result of developments occurring after the date of this press
release. DATASOURCE: Cardiogenesis Corporation CONTACT: William R.
Abbott, Senior Vice President and Chief Financial Officer of
Cardiogenesis Corporation, +1-949-420-1800 Web Site:
http://www.cardiogenesis.com/
Copyright